Objective
T2D, type 2 diabetes
INFLAMMATION, TYPE 2 DIABETES
Edited by: Ahmad Al-Mrabeh, University of Edinburgh, United KingdomReviewed by: Lorenzo Nesti, University of Pisa, Italy; Tsvetelina Velikova, Sofia University, Bulgaria; Priyanka Banerjee, Texas A&M Health Science Center, United States†These authors have contributed equally to this work and share first authorship‡These authors have contributed equally to this work and share last authorshipTo determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement.